10x Genomics CEO Sells $122,800 in Stock

Insider selling activity raises questions about the company's future prospects

Apr. 16, 2026 at 9:27pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate financial machinery and equipment, conveying a sense of institutional power and stability in the banking industry without using any text or symbols.Insider selling activity at 10x Genomics raises questions about the company's future prospects amid broader economic uncertainty.Pleasanton Today

Serge Saxonov, the CEO of 10x Genomics (NASDAQ: TXG), has sold 5,000 shares of the company's stock for a total transaction of $122,800. This represents a 0.43% decrease in Saxonov's position. The sale was disclosed in a filing with the SEC.

Why it matters

Insider selling activity can sometimes signal concerns about a company's future performance or valuation. While a single transaction does not necessarily indicate broader issues, it's worth monitoring 10x Genomics' stock price and any further insider trading activity.

The details

The shares were sold at an average price of $24.56 on April 14, 2026. Following the sale, Saxonov now directly owns 1,167,273 shares in the company, valued at approximately $28.7 million. This is not the first time Saxonov has sold shares - he has made several other sales in recent months, including 5,000 shares in March at an average price of $19.52, and 10,000 shares in March at an average price of $19.13.

  • On April 14, 2026, Saxonov sold 5,000 shares.
  • On March 24, 2026, Saxonov sold 5,000 shares.
  • On March 23, 2026, Saxonov sold 10,000 shares.
  • On February 23, 2026, Saxonov sold 9,632 shares.

The players

Serge Saxonov

The CEO of 10x Genomics, a biotechnology company specializing in advanced genomic analysis solutions.

10x Genomics

A biotechnology company that develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics.

Got photos? Submit your photos here. ›

What they’re saying

“This represents a 0.43% decrease in their position.”

— Serge Saxonov, CEO

What’s next

Investors will be closely watching to see if Saxonov continues to sell shares in the coming months, which could signal broader concerns about the company's outlook.

The takeaway

While a single insider sale does not necessarily indicate broader issues, the recent selling activity by 10x Genomics' CEO is worth monitoring. Investors should consider the company's overall financial performance and growth prospects when evaluating the stock.